CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 14 enrolled
Drug / intervention
Tranexamic Acid +1 moredrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Pregnant women suspected to have placenta accreta with ≥40% risk based on imaging
  • ✓Women with placenta previa and ≥2 prior cesarean sections
  • ✓Any parity (singleton, twin, or other multiple gestations)
  • ✓English or Spanish speaking
Key exclusion· 4
  • ✕Age less than 18 years
  • ✕Personal history of venous or arterial thrombosis (DVT, PE, MI, stroke)
  • ✕Personal history of high-risk clotting disorder (e.g., anti-phospholipid syndrome)
  • ✕Defective color vision (color-blindness)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02806024
NCT02806024Phase 4Completed
CompareCT.gov

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study (TAPPAS): A Randomized, Placebo-controlled Double Blind Trial

University of California, San Francisco·interventional·Posted Jun 20, 2016·Updated Dec 3, 2019

In Brief

A Phase 4 clinical trial evaluating Tranexamic Acid and Placebo Drug for Placenta Accreta and 3 related conditions. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this pilot study is to determine if intravenous tranexamic acid (TXA) is effective for reducing blood loss during high risk surgical procedures related to placenta previa and placenta accreta. TXA is currently used in other types of surgery for patients who are expected to have a large blood loss, such as orthopedic or open heart surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlacenta Accreta, Postpartum Hemorrhage, Cesarean Section, Tranexamic Acid
CountriesUnited States
CollaboratorsCentral California Faculty Medical Group

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 20, 2016
Enrollment StartNov 1, 2016
Primary CompletionJul 1, 2018
Study CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.0 years ago

Interventions

Tranexamic Aciddrug

Placebo Drugdrug

50 cc Normal Saline IV